In this episode of Lung Cancer Considered, host Dr. Stephen Liu discuss some of the highlights from iMig 2023 – the meeting of the International Mesothelioma Interest Group, an IASLC-endorsed meeting held in late June 2023 in Lille, France.

Guests: Dr. Arnaud Scherpereel, the iMig President and 2023 Conference Chair, currently Professor of Pulmonary and Thoracic Oncology at the University Hospital of Lille.

Dr. Jan van Meerbeeck, Professor of Thoracic Oncology at both Ghent and Antwerp University and Chair of Pulmonology at Antwerp University Hospital. He was also co-Chair of the 2023 iMig meeting

This episode of Lung Cancer Considered examines the treatment of EGFR-positive lung cancer in Brazil from early-stage disease to metastatic lung cancer.

Podcast guests:

Dr. Juliana Ominelli, a Brazilian practicing medical oncologist in Rio de Janeiro, Brazil with experience treating EGFR Lung Cancer. She practices at the Brazilian National Cancer Institute –Oncologia DASA.

Dr. Victor Marcondes, thoracic medical oncologist from Rio de Janeiro, Brazil who practices at Oncomed Oncologia and has led several trials in the region focusing on EGFR-positive NSCLC,

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion with two global experts about the current and future roles of liquid biopsy and its use for the treatment of lung cancer.

In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu lead a discussion on the recently completed ASCO 2023 meeting that included presentation of the new overall survival data from the ADAURA trial as well as the New England Journal of Medicine publication on data from KEYNOTE 671.

WCLC 2023 is a global, multi-disciplinary meeting designed for physicians, nurses, clinicians, researchers, scientists, survivors and advocates. This year, the meeting rotates to Singapore and Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by the meeting's three co-chairs for a wide-ranging interview about how attendees can make the most out of their experience during IASLC's flagship annual conference.

LCC in Polish: Overcoming Barriers to Lung Cancer Therapy in Poland

This special Polish-language episode of Lung Cancer Considered focuses on the unique challenges facing clinicians, researchers, and patients in Poland. The podcast also focuses on how physicians help patients overcome barriers to treating lung cancer.

Host: Dr Anna Wrona, Department of Oncology and Radiotherapy, Medical University of Gdansk

Guests:

Professor Rafał Dziadziuszko, M.D., Ph.D., Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre at the Medical University of Gdańsk

Professor Witold Rzyman, M.D., Ph.D. Head, Department of Thoracic Surgery at the Medical University of Gdańsk

In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ROS+1 Fusions in NSCLC, including diagnosis, treatment and new exciting research coming down the pipeline. Her guests are:

Dr. Lorenza Landi, Director of Clinical Trials Unit: Phase 1 and Precision Medicine at the National Cancer Institute Regina Elena in Rome. Dr. Landi has extensive experience and is interested in targeted therapy in lung cancer with a focus on ALK, HER-2/EGFR positive and ROS+1 lung cancer.

Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology, at Henry Ford Cancer Institute in Detroit, Mich. Dr. Gadgeel is also part of the Lung Cancer steering committee for the Southwest Oncology Group and he is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals.

Lung Cancer Treatment and Research in Poland (Polish language) by IASLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on EGFR NSCLC and transformation to small cell lung cancer, a relatively new finding since the introduction of targeted therapy.

Guests are:

Dr. Shigeki Umemura

Dr. Shigeki Umemura is from the Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. His interests include targeted therapy in lung cancer, including genomic profiling of small cell lung cancer, evaluation of tumor microenvironment and its association with response to therapy and resistance mechanisms for disease progression.

Dr. Zofia Piotrowska

Dr. Zofia Piotrowska is an assistant professor of medicine at HMS and clinical researcher and lung cancer medical oncologist at the Massachusetts General Hospital. Dr. Piotrowska has an interest in understanding and overcoming resistance to targeted therapies in lung cancer, particularly among patients with EGFR-mutant NSCLC.

Lung Cancer Considered hosts Dr. Narjust Flores and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial. ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR positive NSCLC. While we have seen targeted therapy in this space ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.